Real-World Data on Inotuzumab Ozogamicin for Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia: A GRELAL-Chile Study.

Cancer Med · 2025 · PMC12427359 · PMID 40938298

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

weakly significantno p-value reported

Still, it is only weakly significant in the column (5) model specification.

also in 1,387 other papers

borderline significanceno p-value reported

This approach allowed us to explore how the inclusion or exclusion of variables with missing data or borderline significance affected the magnitude and direction of key hazard ratios.

also in 7,017 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.